Plain-language summary

This Phase 1 trial is comparing Ropeginterferon alfa-2b against other options for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 1 US location.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Ropeginterferon alfa-2b (DRUG): Will be administered via subcutaneous injection once every 2 weeks

Drugs / treatments

Ropeginterferon alfa-2b

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details